Table I.
Comparison of patients treated with intralesional (IL) sodium stibogluconate (SSG) versus IL meglumine antimoniate (MA) treatment
| Factor | IL SSG Patients (n = 33) | IV MA Patients (n = 67) | p-value |
|---|---|---|---|
| Mean age, years (range) | 23 (5–50) | 25 (10–67) | NS |
| Median age, years | 20 | 20 | NS |
| Gender % male |
27M/6F 81.8% |
51M/16F 76.1% |
NS |
| *PCR testing, N (%) | 3 (9%) | 47 (70%) | 0.0001 |
| Time lag to treatment (range) | 2.5 months (1–6) | 2.8 months (1–7) | NS |
| Mean number of lesions (range) | 3 (1–6) | 4 (1–15) | NS |
| Total number of lesions | 93 | 261 | |
| Failure of prior paromomycin ointment topical treatment, N (%) | 7 (21%) | 11 (16%) | NS |
| No. of IL treatments | 2.5 sessions (range 1–6) | 2 sessions (range 1–4) | NS |
| Cure rate | 91% | 88% | NS |
NS: not statistically significant.
*
PCR was done only in a convenient sample because all the cases were from an endemic area for Leishmania major in Israel.